BioStock: BiBBInstruments eyes an eventful 2023

For medtech company BiBBInstruments, 2022 was a year of achievements as well as extensive regulatory processes. The company took important steps towards the goals of revolutionising the diagnostic tissue sampling of serious cancers and entering into a distribution agreement with a global player. Looking at 2023, BiBB expect to put key regulatory steppingstones behind them. This will lead to an avalanche of new milestones for the company. BioStock contacted CEO Fredrik Lindblad to get his comments on Friday's year-end report.

Read the article at biostock.se:

https://www.biostock.se/en/2023/02/bibbinstruments-eyes-an-eventful-2023

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/